Results 41 to 50 of about 19,821,917 (190)
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease. [PDF]
, 2019 Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have several advantages over VKAs that render them an attractive option for adults with congenital heart disease (CHD). Efficacy and safety data specific to the adult CHD population are emerging.
Mulder, Barbara J. M. +9 more
core +2 more sources
Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [PDF]
The Korean Journal of Internal Medicine, 2023 In the last decade, non-vitamin K antagonist oral anticoagulants (NOACs), a new generation of OACs, were introduced to prevent thromboembolism in patients with atrial fibrillation.
Ki Hong Lee, Hyung Wook Park
doaj +1 more source
International Journal of Cardiology: Heart & Vasculature, 2018 Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia.
Ting-Yung Chang +11 more
doaj +1 more source
Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting [PDF]
BioMed Research International, 2014 The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the ...
Anne-Sophie Dincq +5 more
openaire +3 more sources
Non-Vitamin K Oral Anticoagulants (NOACs)
, 2023 Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have revolutionized the field of anticoagulation therapy, offering a significant advancement over conventional anticoagulants like warfarin.
Elias, Ala
core
How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?
Journal of Education, Health and Sport, 2017 For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs).
Łukasz Wołowiec +5 more
doaj +3 more sources
Non–Vitamin K Antagonist Oral Anticoagulants: The Clinician’s New Challenge
Journal of Osteopathic Medicine, 2015 Abstract Millions of US patients are prescribed oral anticoagulants. Traditionally, oral anticoagulation was achieved with vitamin K antagonists (VKAs). In recent years, non–VKA oral anticoagulants (NOACs) have emerged that provide an effective and convenient alternative to VKAs.
Brian K, Yorkgitis +2 more
openaire +2 more sources
Journal of the Formosan Medical Association, 2020 Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA).
Szu-Ju Chen +5 more
doaj +1 more source
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants [PDF]
, 2018 Background and Purpose- The purpose of this study was to investigate the impact of improved antithrombotic treatment in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants on the incidence of stroke and bleeding in ...
Wettermark, Björn +9 more
core +2 more sources